eosinophilic oesophagitis
Gastroenterology · 2015–2023
4decisions
2medicines
3carried consumer input
7individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| budesonide Treatment of eosinophilic oesophagitis (EoE) in adults. The submission requested changes to current PBS listings to remove the requirement for histological… | Jul 2023 | Recommended | input received |
| budesonide Treatment of eosinophilic oesophagitis (EoE) in adults, including induction of remission and maintenance of remission. | Mar 2021 | Not recommended | input received |
| budesonide Treatment of eosinophilic oesophagitis (EoE) in adults, including both induction of remission and maintenance of remission. | Nov 2021 | Recommended with restriction | 7 individuals |
| amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides Eosinophilic oesophagitis and severe intestinal malabsorption including short bowel syndrome (Alfamino®); eosinophilic oesophagitis (Alfamino® Junior). | Nov 2015 | Recommended with restriction | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.